Market Intelligence, Clinical Progress, and High-Purity Reagents for RAS-MAPK Pathway and Neurofibromatosis Type 1 Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NF1 GAP-Related Domain (GRD) / Mutant Protein High purity (>90%), Endotoxin controlled. Sequence Verified. Optimized for RAS-binding and GAP assays. |
View NF1 Products |
| Gene Delivery | NF1 Promise-ORF / Lentivirus Full-length or GRD domain ORF for stable cell line generation and rescue assays. |
View NF1 Products |
| Benchmark Ab | Anti-NF1 Recombinant Antibody Recombinant positive control for Western Blot, Immunoprecipitation, and IHC. |
View NF1 Products |
| Validator | NF1 siRNA Set For knockdown verification in target-specificity and synthetic lethality screening. |
View NF1 Products |
| Related Target A | KRAS Primary downstream effector regulated by NF1 GAP activity; crucial for GTPase-activation assays. |
View KRAS Products |
| Related Target B | MEK1 Downstream kinase in the MAPK pathway; primary target for NF1-deficient tumor therapies. |
View MEK1 Products |
| Related Target C | SPRED1 Sprouty-related EVH1 domain-containing protein 1; essential scaffold helper that recruits NF1 to the cell membrane. |
View SPRED1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Full-length NF1 expression difficulty (320 kDa) | Truncated, highly stable GAP-Related Domain (GRD, residues 1198–1530) sequence-verified and expressed in insect cells or E. coli. |
| Simulating clinical drug-resistance and loss-of-function mutations | Precision mutant proteins (e.g., NF1-GRD R1276G, K1423E) strictly verified by mass spectrometry. |
| Lack of reliable positive controls | High-affinity clinical benchmark antibodies included for assay standardization. |
| Assaying RAS-GAP activation in vitro | Highly purified, low-endotoxin WT and mutant GRD proteins ensuring low background noise in GTPase assays. |
Live Neurofibromin 1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NF1-related therapeutics is intensifying, with major players shifting focus from traditional downstream MEK inhibitors to direct RAS inhibitors, synthetic lethality targets, and gene correction modalities. As first-generation therapies like Selumetinib establish clinical efficacy in plexiform neurofibromas, the next wave of R&D is targeting the restoration of NF1-GAP function, upstream receptor tyrosine kinase (RTK) inhibition, and synthetic lethal partnerships (such as SHP2 or RAS-GAP direct complexes).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| MEK1/2 Inhibitors | AstraZeneca, SpringWorks Therapeutics | Plexiform Neurofibromas, Low-Grade Gliomas | Pathway validation using NF1 knockdown (siRNA) and downstream MAPK phosphorylation assays. |
| RAS-NF1 Complex Stabilizers | Academic Spin-offs, Biotech Startups | NF1-mutant Sporadic Cancers (Lung, Melanoma) | High-purity NF1-GRD WT and mutant proteins for SPR/FP interaction assays. |
| Gene / mRNA Therapy | In Vivo Gene Therapy Developers | Neurofibromatosis Type 1 (Monogenic correction) | Lentivirus-mediated full-length ORF delivery to evaluate phenotypic rescue. |
| SHP2 / RTK Inhibitors | Novartis, Jacobio Pharmaceuticals | NF1-deficient Solid Tumors (Combination) | Co-immunoprecipitation and binding panels featuring SPRED1 and NF1 complexes. |